ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01672 ASCLETIS-B

Not Yet Opened 01-21 16:08:56

13.520

-0.050

-0.37%

High14.100	Low13.220	Vol2.14M
Open13.570	D1 Closing13.570	Amplitude6.48%
Mkt Cap13.41B	Tradable Cap13.41B	Total Shares992.00M
T/O29.38M	T/O Rate0.22%	Tradable Shares992.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"ASCLETIS-B","latestPrice":13.52,"timestamp":1768982936004,"preClose":13.57,"halted":0,"volume":2144000,"delay":0,"changeRate":-0.0036845983787767655,"floatShares":992000000,"shares":992000000,"eps":-0.33660489103923646,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"01-21 16:08:56","open":13.57,"high":14.1,"low":13.22,"amount":29376222,"amplitude":0.064849,"askPrice":13.52,"askSize":2000,"bidPrice":13.45,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.2972115722272472,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":0,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":13.57,"openAndCloseTimeList":[[1768959000000,1768968000000],[1768971600000,1768982400000]],"volumeRatio":0.693147,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672/tweets","defaultTab":"tweets","newsList":[{"id":"1158406293","title":"ASCLETIS-B (01672) Selects Next-Generation Monthly Subcutaneous GLP-1R/GIPR/GCGR Triple Agonist Peptide ASC37 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1158406293","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158406293?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:56","pubTimestamp":1768903007,"startTime":"0","endTime":"0","summary":"The Board of ASCLETIS-B (01672) announced that it has selected ASC37, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR triple agonist peptide, as a clinical development...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","01672","BK1515","BK1574","BK4144","BK4590","GIPR","BK1191","BK1161","BK4160","01477"],"gpt_icon":0},{"id":"2604317195","title":"Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2604317195","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604317195?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:00","pubTimestamp":1768899651,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application  to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5f9lyN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","01672","BK1161"],"gpt_icon":0},{"id":"2604195395","title":"Ascletis Pharma Inc - Ind Submission for Asc37 Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604195395?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:00","pubTimestamp":1768899618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0E8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2604195313","title":"Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604195313?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:00","pubTimestamp":1768899618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"1130092853","title":"HK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1130092853","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130092853?lang=en_us&edition=fundamental","pubTime":"2026-01-20 11:50","pubTimestamp":1768881036,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01477","BK1574","01672","BK1515","BK1191"],"gpt_icon":0},{"id":"2604403918","title":"Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2604403918","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604403918?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:29","pubTimestamp":1768566548,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to 80 mg and focusing on HbA1c, fasting glucose, weight, and safety outcomes.\nThe company also released Phase II obesity data showing dose‑dependent weight loss and relatively low discontinuation and vomiting rates, underlining ASC30’s potential as an in‑house oral GLP‑1 receptor agonist targeting...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/why-ascletis-pharma-sehk1672-is-up-63-after-fda-clears-asc30","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01672","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"1187850100","title":"Hong Kong Stock Anomaly | Ascletis Pharma-B (01672) Surges Over 6% in Afternoon Trading on Strong ASC30 Data, Company Raises Buyback Cap to HK$500 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1187850100","media":"Stock News","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187850100?lang=en_us&edition=fundamental","pubTime":"2026-01-14 14:37","pubTimestamp":1768372656,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) experienced a surge of over 6% in afternoon trading. As of the time of writing, the stock was up 6.14%, trading at HK$13.66, with a turnover of HK$35.85 million. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","BK1161","01672","01477","BK1515"],"gpt_icon":0},{"id":"2602732510","title":"Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2602732510","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602732510?lang=en_us&edition=fundamental","pubTime":"2026-01-09 12:45","pubTimestamp":1767933927,"startTime":"0","endTime":"0","summary":"Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment planned to start in the first quarter of 2026.\nThe clearance builds on prior Phase II obesity data in which ASC30 delivered dose-dependent weight loss and relatively favorable gastrointestinal tolerability, reinforcing its potential as an oral treatment option across major metabolic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1161","BK1574","01672"],"gpt_icon":0},{"id":"2601000113","title":"Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000113","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601000113?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:44","pubTimestamp":1767602670,"startTime":"0","endTime":"0","summary":"Hong Kong stocks closed mixed Monday as investors parsed macro data from China and closely followed geopolitical developments in Latin America.The Hang Seng Index rose marginally by around 8.77 points","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1725190679.HKD","BK1615","SG9999003461.SGD","BK1610","SG9999014914.USD","LU0414403682.SGD","LU1196710351.USD","LU1813983027.USD","SG9999014906.USD","SG9999000327.SGD","LU0211331839.USD","LU1282649067.USD","LU0084288322.USD","LU0541502299.USD","LU2039709279.SGD","MCHmain","LU2125910849.SGD","LU0882747503.HKD","LU1733274473.HKD","LU1960683339.HKD","SG9999001846.SGD","LU2399975544.HKD","BK1515","LU0683595622.HKD","LU0235996351.USD","LU0594300419.USD","LU1868837722.USD","LU0642271901.SGD","SG9999002828.SGD","LU0348814723.USD","LU1720050803.USD","LU0049853897.USD","LU0823397103.USD","LU0348827113.USD","LU0417516738.SGD","LU1880383366.USD","LU1868837565.USD","LU0106252389.USD","LU1808992512.USD","LU0149721374.USD","IE00B031HY20.USD","LU0791591158.USD","LU0370786039.SGD","LU0898667661.SGD","IE00BZ08YS42.EUR","LU1282649141.HKD","LU1718418525.SGD","LU0823397285.USD","LU0039217434.USD","LU0979878070.USD","LU0577902611.USD","LU1211504680.USD","LU1226288253.USD","LU2097828714.EUR","LU0823041008.USD","HK0000306685.HKD","LU2251237306.USD","LU2097828805.USD","LU0593848301.USD","LU0210527791.USD","LU1880383440.USD","LU0048597586.USD","BK1095","LU0348825331.USD","LU2498475776.HKD","IE0001KFT4U8.USD","LU0561508036.HKD","LU0871576103.HKD","HK0000320264.USD","LU2152927971.USD","LU2265009873.SGD","SG9999014898.SGD","LU0878005551.USD","BK1517","LU1568876251.USD","IE00BQXX3D17.EUR","SG9999001069.SGD","IE00B031HW06.USD","HHImain","LU0873338254.USD","LU0918141887.USD","IE0032431581.USD","BK1589","LU2462611646.USD","LU1235295612.USD","LU0608807433.USD","LU1226288170.HKD","BK1586","BK1618","LU0314109678.HKD","SG9999001903.USD","LU0543330483.HKD","LU0577902538.SGD","LU0326950275.SGD","SG9999015945.SGD","LU0203347892.USD","LU2317271919.USD","BK1531","LU0107464264.USD","LU0164880469.USD","LU0823040885.USD","LU2242644610.SGD","LU0499858602.USD","LU1439102457.SGD","IE00B0169L03.USD","LU0823426480.USD","LU0588545730.USD","LU0572940350.SGD","LU1046422090.SGD","SG9999001051.SGD","LU0181495838.USD","LU1568876335.HKD","LU0072462343.USD","LU0052750758.USD","LU0043850808.USD","LU1629966141.USD","SG9999007991.SGD","LU0329678337.USD","LU2106854487.HKD","LU0823039010.USD","LU1974910355.USD","LU0106259558.USD","LU0823413660.USD","LU1328277881.USD","LU0501845795.SGD","LU0072913022.USD","LU1366334651.USD","IE0003895053.USD","LU0456827905.SGD","LU0345769631.USD","LU2097828557.USD","LU1831875114.USD","LU0359202008.SGD","LU0228367735.SGD","LU0633140727.USD","LU1956131251.USD","LU2097828474.EUR","IE00BQXX3F31.USD","LU0011963245.USD","LU0540923850.HKD","LU0708995583.HKD","LU0229945570.USD","LU0700851271.USD","LU1242518931.SGD","BK1574","LU1770034418.SGD","LU0326948709.USD","LU2362540622.SGD","LU1196710864.SGD","LU1008478684.HKD","LU1515016050.SGD","BK1227","LU0588545904.SGD","SGXZ81514606.USD","LU0307460666.USD","LU2237443978.SGD","BK1609","IE0009570106.USD","LU0067412154.USD","LU0315178854.USD","LU0737861699.HKD","LU1044876610.USD","LU1769817096.USD","LU1251922891.USD","LU0169518387.USD","LU0165289439.USD","LU1188198961.HKD","SG9999001093.SGD","LU0348735423.USD","LU0469268626.HKD","LU1993786604.SGD","LU0132412106.USD","LU2778985437.USD","SG9999017495.SGD","LU0672654166.SGD","LU2257852520.SGD","LU1794554557.SGD","LU1655091459.SGD","IE0034224299.USD","LU0251144936.SGD","LU0821914370.USD","LU2362541513.USD","SG9999015952.SGD","LU1323998911.USD","513600","LU0463099449.HKD","LU1981816686.USD","LU0348723411.USD","IE00BPRC5H50.USD","LU0348784397.USD","LU0327786744.USD","SGXZ51526630.SGD","LU1328615791.USD","LU0210533765.USD","LU2237443549.SGD","IE0003851619.USD","LU1224444064.USD","SG9999004220.SGD","LU0449509016.USD","SG9999013353.USD","LU2476274720.SGD","IE0008368411.USD","LU1734074674.USD","LU2237443465.HKD","LU0675040207.SGD","LU1316542783.SGD","IE0032834883.USD","LU0127658192.USD","LU2237443895.HKD","LU0862451837.USD","LU0648948544.HKD","IE0008368742.USD","LU0823038988.USD","LU0203345920.USD","IE00B543WZ88.USD","LU1303224171.USD","LU0828238088.HKD","IE0008369823.USD","LU2051468812.USD","LU0320764755.SGD","LU0128522157.USD","LU0441854154.USD","LU1951186391.HKD","LU1733274390.USD","01672","LU0516422366.SGD","LU2097828631.EUR","LU1226287529.USD","LU0588546209.SGD","LU1242518857.USD","LU1282651121.HKD","IE00BF5LJ272.USD","LU0345769128.USD","LU1868838027.USD","LU2008162690.USD","LU0054450605.USD","LU0449515922.USD","LU1102505762.USD","LU0163747925.USD","LU0608807946.USD","LU2251237488.HKD","LU2449936058.SGD","SG9999014880.SGD","MHImain","LU0431992006.USD","LU1105468828.SGD","LU0607220059.USD","LU1917777945.USD","LU1481107354.HKD","LU0819121731.USD","IE00B031J352.USD","LU0594300179.USD","LU0572944931.SGD","LU0164865239.USD","LU0541501648.USD","LU2023250504.SGD","LU2279701549.SGD","LU0269904917.USD","LU2125910500.SGD","IE0031814852.USD","LU0348783662.USD","LU2237443622.USD","LU0029874905.USD","LU0784639295.USD","LU0786609619.USD","LU0348805143.USD","LU0117844026.USD","LU0348783233.USD","LU0259732245.USD","SG9999015986.USD","IE0003795394.USD","LU0828237510.HKD","LU0196878994.USD","LU1439103000.SGD","LU1719994722.HKD","LU0880133367.SGD","LU0531971595.HKD","LU1785774172.SGD","LU0488056044.USD","LU0140636845.USD","LU0737861772.HKD","LU0384037296.USD","LU0455707207.USD","BK1516","LU0348788117.USD","LU0531970944.HKD","LU0918141705.HKD","LU0797268264.HKD","LU0164872284.USD","LU1804176565.USD","SG9999001689.USD","IE00B3M56506.USD","SG9999018865.SGD","LU0878004406.USD","LU0175139822.USD","LU0345775950.USD","LU1807302812.USD","LU1688375341.USD","LU2362541273.HKD","LU1102505929.USD","IE00B5MMRT66.SGD","LU0886674414.USD","LU0577902371.SGD","LU0651947912.USD","LU0210526637.USD","LU0823426308.USD","IE00B0169N27.USD","LU0456842615.SGD","LU0211977185.USD","IE00BZ08YT58.USD","TCHmain","SG9999018857.SGD","LU0149534421.HKD","LU0651946864.USD","SG9999014674.SGD","LU1051769294.HKD","IE00B0JY6N72.USD","SG9999001226.SGD","LU0061477393.USD","SG9999000459.SGD","LU0320764243.SGD","BK1161","LU0509642566.USD","LU1152091754.HKD","BK1591","LU0499858438.USD","HK0000306701.USD","LU0192582467.USD","GB00BDT5M118.USD","SG9999015978.USD","LU0577902454.USD","LU1961090484.USD","LU0831103253.SGD","LU2476274308.USD","LU2226246903.HKD","LU0047713382.USD","LU1048596156.SGD","LU0228659784.USD","LU0348816934.USD","LU0106959298.USD","LU2293587155.HKD","LU0819123356.HKD","LU0143863784.USD","SG9999002463.SGD","LU2087589342.USD","LU2177674079.SGD","LU1366334578.USD","SGXZ99366536.SGD","IE00B067MR52.USD","SG9999006514.SGD","LU0516423174.USD","LU0890818403.SGD","LU1048484197.HKD","IE00BZ08YR35.GBP","IE00B8L5B284.USD","LU0417516902.SGD","LU1282649810.SGD","LU0070217475.USD","LU0828237940.HKD","LU0117841782.USD","IE00BQXX3C00.GBP","LU0611395673.USD","LU1044875133.USD","LU1051768304.USD","LU0543330566.HKD","LU0588545490.SGD","HTCD.SI","LU1224709979.USD","LU0261947096.USD","LU0244354667.USD","LU1675838814.USD","LU0516423091.SGD","IE00B29SXG58.USD","BK1521","LU1282651048.USD","BK1526","LU0417516571.SGD","LU0048388663.USD","LU0048580855.USD","LU0516422952.EUR","LU0328353924.USD","LU0577902298.EUR","LU3063872942.SGD","LU0345776255.USD","LU1152091168.USD","LU0856984785.SGD","SGXZ90724238.SGD","LU1814569148.SGD","LU1226288097.SGD","LU0708995153.HKD","LU0516422440.USD","LU0650527681.SGD","LU0738912210.USD","LU0173614495.USD","LU1810669033.SGD","LU0320764599.SGD","LU0188438112.USD","SG9999006597.SGD","LU0589944569.HKD","LU0634319403.HKD","LU1023057109.AUD","LU0289960550.SGD","LU0972618739.USD","LU0287142896.SGD","BK1608","LU0051755006.USD","LU0029875118.USD","LU1769817179.HKD","LU0080751232.USD","LU0329678170.USD","LU0293314216.USD","LU1048588211.SGD","LU0231483743.USD","LU0823413587.USD","BK1502","LU0359201885.HKD","LU2045819591.USD","LU2237443382.USD","LU0143863198.USD","SG9999000418.SGD","LU0633140560.USD","LU1226287792.SGD","LU0214875030.USD","SG9999002562.SGD","LU0054237671.USD","LU0868486357.SGD","LU1196710195.USD","LU1226287875.USD","02833","LU0791590937.USD","IE00B97KM107.HKD","LU0502904849.HKD","LU0254981946.USD","LU1044874839.SGD","LU1770036033.HKD","LU0572939691.SGD","LU1504937902.USD","HK0000320223.HKD","LU0865486749.SGD","LU0985320562.USD","LU0049112450.USD","LU2247934214.USD","LU0261950983.USD","LU0605514214.HKD","LU2133065610.SGD","LU0862451753.SGD","LU0456846285.SGD","LU0396098781.USD","LU0128522744.USD","LU1883866441.USD","SGXZ31699556.SGD","LU1282648689.USD","IE00BGV7N243.SGD","LU0359201612.USD","LU0096374516.USD","LU1642822792.SGD","IE00B8HQ1Z84.USD","LU0264606111.USD"],"gpt_icon":1},{"id":"2601731440","title":"BRIEF-Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601731440","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601731440?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:14","pubTimestamp":1767575682,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II StudyJan 5 (Reuters) - Ascletis Pharma Inc 1672.HK:RECEIVES FDA IND CLEARANCE FOR ASC30 PHASE II STUDYFurther company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y30A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"gpt_icon":0},{"id":"1177932262","title":"ASCLETIS-B (01672) Announces FDA Approval of IND for 13-Week Phase II Study of ASC30 in Diabetic Subjects","url":"https://stock-news.laohu8.com/highlight/detail?id=1177932262","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177932262?lang=en_us&edition=fundamental","pubTime":"2026-01-05 08:18","pubTimestamp":1767572313,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that it has recently received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for its oral small molecule...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","IND","BK1515","01672","01477","BK1574"],"gpt_icon":0},{"id":"2601020033","title":"Ascletis Pharma Inc - Receives FDA Ind Clearance for Asc30 Phase Ii Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601020033?lang=en_us&edition=fundamental","pubTime":"2026-01-05 08:01","pubTimestamp":1767571288,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y30A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"2601035020","title":"Ascletis Pharma Wins FDA IND Clearance for Phase II Diabetes Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601035020","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601035020?lang=en_us&edition=fundamental","pubTime":"2026-01-05 08:01","pubTimestamp":1767571279,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced that it has received Investigational New Drug  clearance from the U.S. Food and Drug Administration  for a 13-week Phase II clinical study of its oral small molecule GLP-1 candidate, ASC30, in participants with type 2 diabetes mellitus. The upcoming study will be randomized, double-blind, placebo-controlled, and multi-center, aiming to evaluate the efficacy, safety, and tolerability of ASC30. Enrollment for the trial is expected to begin in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 05, 2026, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc0dVWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"1174407833","title":"Zhixiang Hong Kong Stock Repurchase Statistics | January 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1174407833","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174407833?lang=en_us&edition=fundamental","pubTime":"2026-01-01 09:13","pubTimestamp":1767230019,"startTime":"0","endTime":"0","summary":"A total of 58 companies conducted share buybacks on December 31, 2025. Among them, TENCENT (00700) executed the largest buyback by value, repurchasing 1.061 million shares for HK$635 million. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0856984785.SGD","LU0823041008.USD","LU1226288097.SGD","SG9999015952.SGD","LU0605514214.HKD","LU0269904917.USD","LU0828237510.HKD","LU0348735423.USD","LU1769817179.HKD","BK1542","BK1105","LU2106854487.HKD","LU0181495838.USD","LU2279701549.SGD","LU1720050803.USD","SG9999001846.SGD","BK1109","IE00BZ08YT58.USD","LU0320764755.SGD","LU0880133367.SGD","IE00B29SXG58.USD","LU1242518857.USD","BK1531","SG9999003461.SGD","LU1810669033.SGD","06609","LU0979878070.USD","LU1023057109.AUD","BK1583","IE0034224299.USD","LU0348766576.USD","LU1152091168.USD","LU0541502299.USD","SG9999007991.SGD","LU1242518931.SGD","LU1102505762.USD","BK1161","LU0048597586.USD","LU0096374516.USD","LU0683595622.HKD","LU2097828714.EUR","LU0502904849.HKD","BK1587","LU2265009873.SGD","LU0823426308.USD","LU0359202008.SGD","LU2476274308.USD","LU0823413660.USD","01516","LU1868837722.USD","LU0463099449.HKD","BK1506","BK1142","BK1515","02678","LU1770036033.HKD","LU2498475776.HKD","LU0320764599.SGD","LU1044874839.SGD","LU0228367735.SGD","BK1144","LU1808992512.USD","LU0543330566.HKD","LU2237443465.HKD","SGXZ99366536.SGD","LU0823038988.USD","LU0348784397.USD","LU1725190679.HKD","06100","BK1128","LU0449515922.USD","01897","LU0106259558.USD","LU0054450605.USD","SG9999006597.SGD","LU0370786039.SGD","LU0175139822.USD","LU0865486749.SGD","SGXZ81514606.USD","LU0823413587.USD","LU0261950983.USD","09857","LU1880383440.USD","LU0608807946.USD","LU0348805143.USD","LU0738912210.USD","01995","LU1733274390.USD","BK1104","LU2097828805.USD","IE0031814852.USD","LU0651947912.USD","LU0067412154.USD","LU0188438112.USD","LU2226246903.HKD","LU2237443549.SGD","LU0173614495.USD","BK1095","LU0293314216.USD","LU0132412106.USD","BK1131","LU2399975544.HKD","LU2177674079.SGD","LU1770034418.SGD","BK1518","BK1167","SGXZ90724238.SGD","LU2460026573.USD","00700","HK0000165453.HKD","IE00B97KM107.HKD","LU1481107354.HKD","LU0061477393.USD","LU1048596156.SGD","LU1688375341.USD","BK1521","02142","IE0032834883.USD","HXXD.SI","09896","LU1048588211.SGD","LU1226287529.USD","LU1439103000.SGD","LU0577902371.SGD","06098","GB00BDT5M118.USD","LU0531970944.HKD","LU1655091459.SGD","SG9999001903.USD","LU0823040885.USD","LU0051755006.USD","LU0588545730.USD","01588","LU0417516902.SGD","LU1282651121.HKD","00345","IE00B5MMRT66.SGD","LU2152927971.USD","BK1566","03798","LU0588545904.SGD","09878","HK0000320223.HKD","LU1675838814.USD","BK1229","LU1102505929.USD","LU1956131251.USD","LU0862451837.USD","LU2237443978.SGD","LU0648948544.HKD","02621","BK1195","LU0128522157.USD","SG9999001226.SGD","02391","BK1100","LU2087589342.USD","LU1188198961.HKD","LU0047713382.USD","LU1981816686.USD","LU0345769128.USD","BK1249","LU0314109678.HKD","LU0823397103.USD","IE0003795394.USD","LU0611395673.USD","LU2133065610.SGD","01458","LU1226287792.SGD","09922","LU0642271901.SGD","LU2362541513.USD","LU0072462343.USD","LU1105468828.SGD","LU1196710351.USD","LU1226287875.USD","02652","LU0254981946.USD","LU0320764243.SGD","LU0455707207.USD","SG9999000459.SGD","LU2449936058.SGD","IE00B0169L03.USD","LU0737861699.HKD","LU2125910500.SGD","LU1568876335.HKD","LU1785774172.SGD","LU0700851271.USD","LU0244354667.USD","LU0608807433.USD","LU1804176565.USD","LU0348816934.USD","LU1814569148.SGD","LU1813983027.USD","LU0307460666.USD","LU0070217475.USD","IE0009570106.USD","SG9999018857.SGD","BK1500","LU0211331839.USD","LU1807302812.USD","IE00B8HQ1Z84.USD","SG9999004220.SGD","SG9999014898.SGD","LU1323998911.USD","LU2237443382.USD","LU0011963245.USD","LU0516422440.USD","LU1235295612.USD","LU0149534421.HKD","BK1155","LU0873338254.USD","SG9999006514.SGD","LU1831875114.USD","LU0588546209.SGD","LU0821914370.USD","LU1051769294.HKD","BK1613","LU1366334578.USD","IE00BZ08YR35.GBP","LU0251144936.SGD","01868","IE0003851619.USD","SG9999001069.SGD","BK1608","BK1526","BK1619","LU2023250504.SGD","LU0650527681.SGD","LU0541501648.USD","BK1183","HK0000320264.USD","BK1246","LU0315178854.USD","LU1152091754.HKD","LU0106252389.USD","LU0203345920.USD","LU2237443895.HKD","BK1523","LU0675040207.SGD","LU0043850808.USD","LU0384037296.USD","LU0823397285.USD","LU1008478684.HKD","02121","LU0499858438.USD","LU0577902298.EUR","LU2476274720.SGD","LU0192582467.USD","BK1160","LU0054237671.USD","LU0164880469.USD","LU0117841782.USD","SGXZ51526630.SGD","LU0456842615.SGD","LU1504937902.USD","LU1282649141.HKD","LU0577902454.USD","LU0797268264.HKD","SG9999014674.SGD","LU0169518387.USD","LU0348814723.USD","LU1282649810.SGD","BK1589","LU0878004406.USD","06868","BK1215","02886","LU0196878994.USD","IE00BQXX3F31.USD","LU1951186391.HKD","LU0862451753.SGD","BK1237","LU0540923850.HKD","LU1515016050.SGD","02038","IE0032431581.USD","06608","09669","LU0396098781.USD","IE00B0JY6N72.USD","LU2247934214.USD","IE0003895053.USD","LU0348827113.USD","HK0000252160.HKD","LU3063872942.SGD","HK0000306685.HKD","03650","LU0211977185.USD","LU0588545490.SGD","LU0828237940.HKD","LU1282649067.USD","LU1868837565.USD","BK1193","SG9999018865.SGD","LU0259732245.USD","00909","LU0594300419.USD","SG9999001093.SGD","LU0737861772.HKD","LU0235996351.USD","LU0326948709.USD","IE00B543WZ88.USD","BK1604","02517","LU1568876251.USD","BK1258","02869","LU0516423091.SGD","LU0516423174.USD","LU1960683339.HKD","LU0786609619.USD","01024","LU0577902611.USD","BK1590","01600","LU0287142896.SGD","SG9999017495.SGD","LU2097828631.EUR","LU0048388663.USD","BK1117","09886","LU0831103253.SGD","XIACY","LU0784639295.USD","LU0143863784.USD","LU0819123356.HKD","LU1642822792.SGD","SG9999000327.SGD","LU2045819591.USD","LU2251237306.USD","LU1734074674.USD","06831","LU0072913022.USD","06078","IE00B031HW06.USD","LU1974910355.USD","01274","LU0633140727.USD","LU0140636845.USD","SGXZ31699556.SGD","LU0607220059.USD","LU0326950275.SGD","LU1439102457.SGD","LU1224444064.USD","LU2237443622.USD","BK1116","LU0359201612.USD","LU0543330483.HKD","LU0561508036.HKD","LU1282651048.USD","LU2293587155.HKD","SG9999015986.USD","LU0516422952.EUR","LU0868486357.SGD","LU1719994722.HKD","LU1196710864.SGD","LU0049112450.USD","LU0261947096.USD","BK1247","LU0985320562.USD","LU0918141705.HKD","BK1618","LU1883866441.USD","LU1328615791.USD","LU0348783233.USD","LU0345775950.USD","LU0708995583.HKD","LU1917777945.USD","BK1502","LU0359201885.HKD","LU0048580855.USD","LU0572940350.SGD","LU1282648689.USD","LU1794554557.SGD","LU0231483743.USD","LU0456827905.SGD","BK1609","LU2251237488.HKD","LU1044876610.USD","LU2778985437.USD","LU1718418525.SGD","LU0163747925.USD","BK1574","LU0052750758.USD","LU2317271919.USD","02299","IE00B0169N27.USD","BK1575","LU0572939691.SGD","LU0327786744.USD","LU0049853897.USD","LU0918141887.USD","IE0001KFT4U8.USD","LU0128522744.USD","LU0143863198.USD","LU0531971595.HKD","IE00B031HY20.USD","LU0871576103.HKD","LU1629966141.USD","BK1586","LU0791591158.USD","81810","LU0708995153.HKD","LU2125910849.SGD","LU0634319403.HKD","LU0228659784.USD","LU0164865239.USD","LU0348825331.USD","LU1051768304.USD","06887","LU0106959298.USD","SG9999001689.USD","LU1226288170.HKD","LU0264606111.USD","LU0449509016.USD","LU0348788117.USD","IE0008368742.USD","LU1226288253.USD","LU2257852520.SGD","LU0882747503.HKD","02509","LU1251922891.USD","LU1196710195.USD","LU1303224171.USD","BK1504","LU0414403682.SGD","LU2008162690.USD","IE00BF5LJ272.USD","00314","01672","LU1224709979.USD","LU0127658192.USD","LU0210533765.USD","LU0456846285.SGD","LU1211504680.USD","LU2462611646.USD","LU0229945570.USD","LU0898667661.SGD","LU2362540622.SGD","BK1233","LU1961090484.USD","SG9999002828.SGD","LU0329678337.USD","BK1591","IE00BPRC5H50.USD","LU0165289439.USD","LU0210526637.USD","LU0164872284.USD","01810","LU0488056044.USD","LU1880383366.USD","02419","LU0577902538.SGD","BK1615","LU1046422090.SGD","LU0441854154.USD","BK1607","81024","IE0008369823.USD","02018","IE00BZ08YS42.EUR","LU0469268626.HKD","BK1132","LU0328353924.USD","LU0509642566.USD","LU0149721374.USD","LU1868838027.USD","LU0828238088.HKD","LU0972618739.USD","LU2097828557.USD","IE00BQXX3C00.GBP","SG9999014880.SGD","LU0499858602.USD","LU0589944569.HKD","BK1209","LU0572944931.SGD","LU0593848301.USD","BK1191","LU2051468812.USD","02598","LU2362541273.HKD","LU0029875118.USD","HTCD.SI","IE00B067MR52.USD","02219","IE00B031J352.USD","LU0210527791.USD","SG9999002463.SGD","LU0084288322.USD","IE00B3M56506.USD","LU0345769631.USD","BK1124","TCHmain","LU0117844026.USD","09959","BK1517","LU1316542783.SGD","LU0080751232.USD","IE00BQXX3D17.EUR","LU0214875030.USD","BK1221","LU1044875133.USD","02586","01651","LU2488822045.USD","LU0823039010.USD","SG9999001051.SGD","HK0000252152.HKD","BK1516","LU0289960550.SGD","02866","LU0329678170.USD","LU0417516571.SGD","SG9999002562.SGD","LU2242644610.SGD","SG9999015945.SGD","HK0000306701.USD","LU0348767384.USD","IE00B8L5B284.USD","09966","IE0008368411.USD","LU1048484197.HKD","HK0000500386.USD","LU0633140560.USD","LU0431992006.USD","BK1585","BK1535","BK1549","LU2097828474.EUR","SG9999015978.USD","LU0501845795.SGD","LU0345776255.USD","LU0672654166.SGD","LU1993786604.SGD","LU0791590937.USD","LU1328277881.USD","LU1366334651.USD","SG9999014906.USD","IE00BGV7N243.SGD","LU0878005551.USD","LU0886674414.USD","LU0417516738.SGD","LU0651946864.USD","SG9999014914.USD","LU0107464264.USD","LU0819121731.USD","LU0516422366.SGD","LU0029874905.USD","SG9999013353.USD","LU0348723411.USD","LU0594300179.USD","BK1610","SG9999000418.SGD","02416","BK1253","LU0039217434.USD","LU0823426480.USD","LU0890818403.SGD","LU0348783662.USD","LU1769817096.USD","08017","BK1508","LU2039709279.SGD","LU1733274473.HKD","LU0203347892.USD"],"gpt_icon":1},{"id":"1100686104","title":"Ascletis-B (01672) Repurchases 200,000 Shares for HK$2.4829 Million on December 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1100686104","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100686104?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:26","pubTimestamp":1767003985,"startTime":"0","endTime":"0","summary":"Ascletis-B (01672) announced that on December 29, 2025, the company repurchased 200,000 shares at a price range of HK$12.17 to HK$12.66 per share, with a total expenditure of HK$2.4829 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1161","01672","BK1574","01477","BK1515"],"gpt_icon":0},{"id":"2595781833","title":"Ascletis Pharma Repurchases 200,000 Shares for HK$2.48 Million in HKEX Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781833","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595781833?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:20","pubTimestamp":1767003625,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 200,000 ordinary shares at a total aggregate price of HKD 2,482,860. The shares were repurchased for cancellation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL1kRr2W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"1191518848","title":"Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with \"Buy\" Rating, Sets Target Price at HK$18.38","url":"https://stock-news.laohu8.com/highlight/detail?id=1191518848","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191518848?lang=en_us&edition=fundamental","pubTime":"2025-12-29 10:40","pubTimestamp":1766976048,"startTime":"0","endTime":"0","summary":"Orient Securities has issued a research report forecasting Ascletis Pharma-B's (01672) earnings per share for 2025-2027 to be -0.32, -0.35, and -0.38 yuan, respectively. Using an absolute valuation...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK0188","03958","BK1191","BK0276","BK1161","BK1515","BK1147","600958","BK1564","BK0183","BK1574","BK0012","01672","BK0028"],"gpt_icon":0},{"id":"2593421163","title":"Ascletis Pharma Files HKEX Disclosure on Repurchase of 100,000 Shares at HKD 1,254,850","url":"https://stock-news.laohu8.com/highlight/detail?id=2593421163","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593421163?lang=en_us&edition=fundamental","pubTime":"2025-12-24 14:13","pubTimestamp":1766556820,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 100,000 shares at a total aggregate price of HKD 1,254,850. The repurchased shares are to be cancelled in accordance with the company’s share buyback mandate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL34HC1l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"1197161579","title":"HK Stock Buyback Summary | Dec 24","url":"https://stock-news.laohu8.com/highlight/detail?id=1197161579","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197161579?lang=en_us&edition=fundamental","pubTime":"2025-12-24 09:18","pubTimestamp":1766539098,"startTime":"0","endTime":"0","summary":"On December 23, 2025, multiple Hong Kong-listed companies conducted share buybacks. Among them, Tencent (00700) recorded the highest buyback amount, repurchasing 1.051 million shares for HKD 636...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1221","LU0315179316.USD","IE0003895053.USD","SG9999006597.SGD","LU1323998911.USD","LU0828237510.HKD","BK1505","01458","LU0572944931.SGD","LU2237443549.SGD","LU1282649141.HKD","LU0456827905.SGD","IE00BPRC5H50.USD","06826","LU1102505762.USD","LU2152927971.USD","LU0871576103.HKD","LU0348784397.USD","LU0228659784.USD","IE0031814852.USD","LU1226288253.USD","BK1613","LU0577902611.USD","LU2476274308.USD","BK1502","LU0251144936.SGD","LU0049853897.USD","LU0449515922.USD","LU0683595622.HKD","LU0210526637.USD","02678","LU2317271919.USD","IE00B8HQ1Z84.USD","BK1104","LU2257852520.SGD","BK1148","LU0455707207.USD","LU0708995583.HKD","LU0607220059.USD","LU1719994722.HKD","BK1504","LU2237443465.HKD","LU0127658192.USD","LU0244354667.USD","LU0651946864.USD","LU0449509016.USD","LU1733274473.HKD","LU0072462343.USD","BK1612","LU0210527791.USD","01600","IE0008368742.USD","LU0784639295.USD","LU1251922891.USD","SG9999000418.SGD","LU1226287875.USD","LU0117844026.USD","LU0348783662.USD","LU0072913022.USD","LU0175139822.USD","LU0823413587.USD","02886","LU0307460666.USD","LU0054450605.USD","LU2133065610.SGD","LU0165289439.USD","LU0048597586.USD","LU1883866441.USD","02038","LU0106252389.USD","LU0117841782.USD","LU0203345920.USD","BK1228","LU0051755006.USD","LU0797268264.HKD","LU1196710195.USD","LU0070217475.USD","LU0329678337.USD","LU0211977185.USD","BK1589","SG9999002463.SGD","BK1149","02299","LU0886674414.USD","BK1521","SG9999013353.USD","LU0456846285.SGD","LU0264606111.USD","LU1282651121.HKD","LU0541502299.USD","LU1282651048.USD","LU0577902454.USD","SG9999004220.SGD","09923","LU0786609619.USD","IE0008369823.USD","01588","LU0823426480.USD","BK1110","LU0642271901.SGD","LU1242518857.USD","01810","LU0326948709.USD","08188","LU0738912210.USD","LU1733274390.USD","LU1951186391.HKD","LU2293587155.HKD","SG9999006514.SGD","LU0181495838.USD","BK1597","LU0188438112.USD","LU1770034418.SGD","LU0261950983.USD","SG9999015952.SGD","LU0543330483.HKD","EVS.SI","LU0821914370.USD","LU2237443895.HKD","BK1119","HK0000320264.USD","BK1253","LU0543330566.HKD","LU0823039010.USD","LU0048388663.USD","LU1568876251.USD","BK1556","LU1048588211.SGD","BK1095","LU0985320562.USD","LU0823413660.USD","LU0856984785.SGD","LU1048484197.HKD","81810","LU0164865239.USD","LU0289960550.SGD","LU0214875030.USD","LU2362541513.USD","LU0203347892.USD","SGXZ99366536.SGD","SG9999014880.SGD","HK0000320223.HKD","BK1610","LU2399975544.HKD","LU0463099449.HKD","LU2362541273.HKD","LU0231483743.USD","BK1103","SGXZ81514606.USD","SG9999014898.SGD","LU0831103253.SGD","LU0898667661.SGD","LU0414403682.SGD","LU1328277881.USD","LU2226246903.HKD","BK1193","LU0348805143.USD","BK1608","LU0791590937.USD","LU0878005551.USD","LU0737861772.HKD","IE00BF5LJ272.USD","LU1810669033.SGD","LU0516422440.USD","LU0648948544.HKD","LU0823041008.USD","IE0003851619.USD","LU0164872284.USD","LU0441854154.USD","IE00B0169N27.USD","LU2476274720.SGD","LU0417516738.SGD","LU1770036033.HKD","LU0140636845.USD","SG9999000459.SGD","LU0516422952.EUR","LU0608807946.USD","02392","03888","LU0865486749.SGD","LU0211331839.USD","00947","00434","LU1048596156.SGD","LU0605514214.HKD","LU0588545730.USD","IE00B0JY6N72.USD","02121","IE00BZ08YS42.EUR","02018","IE00BQXX3C00.GBP","LU1794554557.SGD","LU0359201885.HKD","LU0873338254.USD","LU0634319403.HKD","LU1242518931.SGD","LU2237443382.USD","SG9999017495.SGD","LU1868837722.USD","LU1769817179.HKD","LU1960683339.HKD","LU0029874905.USD","LU1961090484.USD","LU1481107354.HKD","LU2498475776.HKD","01919","LU0259732245.USD","09857","LU1629966141.USD","LU0737861699.HKD","01583","LU1813983027.USD","BK1207","SGXZ90724238.SGD","IE0008368411.USD","BK1591","02251","LU0588545904.SGD","LU1196710864.SGD","01672","HK0000306701.USD","LU0164880469.USD","IE00BGV7N243.SGD","LU1981816686.USD","LU0348767384.USD","LU0516423174.USD","SG9999015986.USD","BK1618","LU0192582467.USD","LU1974910355.USD","SG9999002828.SGD","LU0572939691.SGD","80175","SG9999001689.USD","BK1229","LU2097828631.EUR","LU0862451837.USD","SG9999001846.SGD","LU2097828714.EUR","BK1596","SG9999018857.SGD","02367","LU2125910500.SGD","00700","HK0000252160.HKD","HTCD.SI","LU1831875114.USD","BK1607","LU0828238088.HKD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU2106854487.HKD","LU0651947912.USD","IE0032431581.USD","LU0633140560.USD","LU2449936058.SGD","09959","SG9999007991.SGD","SG9999018865.SGD","IE00B031HW06.USD","LU0593848301.USD","LU1868837565.USD","BK1518","LU0143863784.USD","IE00B8L5B284.USD","LU0048580855.USD","LU0577902538.SGD","BK1170","LU1366334578.USD","SG9999001051.SGD","BK1615","HK0000306685.HKD","09878","SG9999015978.USD","02869","LU1224709979.USD","LU0501845795.SGD","LU0327786744.USD","LU0287142896.SGD","LU2097828474.EUR","BK1609","LU0516422366.SGD","06078","LU0675040207.SGD","LU0650527681.SGD","BK1593","LU0882747503.HKD","BK1516","LU0293314216.USD","00175","TCHmain","IE00BZ08YR35.GBP","BK1542","LU1235295612.USD","LU0052750758.USD","LU0633140727.USD","SG9999000327.SGD","LU0054237671.USD","LU0067412154.USD","SG9999014914.USD","LU0106959298.USD","LU0791591158.USD","LU0359201612.USD","SG9999015945.SGD","LU0823038988.USD","LU0417516902.SGD","LU0107464264.USD","LU1642822792.SGD","LU1328615791.USD","LU1917777945.USD","LU0469268626.HKD","LU0128522744.USD","LU0314109678.HKD","LU2265009873.SGD","LU2279701549.SGD","02167","BK1517","LU0608807433.USD","02219","LU1102505929.USD","BK1237","SG9999003461.SGD","LU2247934214.USD","BK1249","LU0029875118.USD","09669","LU0348827113.USD","IE00BZ08YT58.USD","LU1725190679.HKD","IE00B067MR52.USD","LU0541501648.USD","IE00B031HY20.USD","LU0868486357.SGD","LU2237443978.SGD","IE00BQXX3D17.EUR","LU2051468812.USD","LU2251237306.USD","BK1167","LU0163747925.USD","IE00B29SXG58.USD","LU0499858602.USD","09886","LU0359202008.SGD","LU0320764599.SGD","LU0823397285.USD","LU0588545490.SGD","LU1880383366.USD","LU0456842615.SGD","LU0589944569.HKD","LU1224444064.USD","LU1814569148.SGD","LU1226288097.SGD","LU0345775950.USD","LU0261947096.USD","LU0594300179.USD","01995","BK1586","SG9999001069.SGD","LU2097828805.USD","LU0516423091.SGD","LU0348788117.USD","LU0228367735.SGD","LU0502904849.HKD","LU2177674079.SGD","SGXZ51526630.SGD","LU0823426308.USD","LU2251237488.HKD","LU1807302812.USD","LU2460026573.USD","BK1585","00732","LU0509642566.USD","LU2462611646.USD","02171","IE0032834883.USD","LU1044874839.SGD","BK1575","LU0348723411.USD","LU0531971595.HKD","LU2360107325.USD","LU1044876610.USD","BK1117","BK1535","00697","BK1246","LU0396098781.USD","SG9999002562.SGD","LU1861219969.SGD","LU0320764243.SGD","LU0210533765.USD","LU0096374516.USD","LU2023250504.SGD","BK1583","LU0106259558.USD","LU0348783233.USD","LU0823040885.USD","BK1258","LU0345769631.USD","LU0254981946.USD","LU1568876335.HKD","LU0039217434.USD","LU1282649810.SGD","LU0315178854.USD","LU0918141705.HKD","LU0828237940.HKD","LU0708995153.HKD","LU0196878994.USD","IE0001KFT4U8.USD","LU2097828557.USD","BK1109","LU0561508036.HKD","BK1142","LU0862451753.SGD","SGXZ31699556.SGD","00314","LU0269904917.USD","LU0972618739.USD","LU0169518387.USD","HK0000500386.USD","LU2488822045.USD","01317","BK1604","LU0488056044.USD","LU1804176565.USD","IE00B3M56506.USD","LU1769817096.USD","LU0229945570.USD","BK1183","LU0049112450.USD","LU1226287792.SGD","LU1868838027.USD","BK1155","LU0819123356.HKD","LU1152091754.HKD","LU1051768304.USD","LU0149721374.USD","SG9999001093.SGD","LU1188198961.HKD","LU1675838814.USD","01024","IE00B97KM107.HKD","LU0572940350.SGD","LU0345776255.USD","LU0173614495.USD","LU0577902298.EUR","01773","LU0047713382.USD","LU1023057109.AUD","LU2125910849.SGD","LU0149534421.HKD","LU2008162690.USD","06868","LU0320764755.SGD","LU0611395673.USD","02598","LU0011963245.USD","GB00BDT5M118.USD","BK1587","LU0979878070.USD","LU1808992512.USD","LU0588546209.SGD","LU1439102457.SGD","LU0880133367.SGD","LU3063872942.SGD","LU2039709279.SGD","LU0061477393.USD","LU0348816934.USD","LU1152091168.USD","BK1515","XIACY","LU1785774172.SGD","LU1734074674.USD","LU2242644610.SGD","LU2237443622.USD","LU1282649067.USD","LU0672654166.SGD","BK1161","LU1196710351.USD","LU2045819591.USD","LU0594300419.USD","IE00BQXX3F31.USD","BK1523","LU0878004406.USD","BK1619","BK1590","BK1566","LU0890818403.SGD","01907","BK1526","BK1574","LU1366334651.USD","BK1500","00799","LU0431992006.USD","LU0384037296.USD","LU0345769128.USD","LU1504937902.USD","LU0499858438.USD","LU0540923850.HKD","LU0348814723.USD","LU2087589342.USD","BK1124","LU0370786039.SGD","LU1046422090.SGD","LU0132412106.USD","LU1044875133.USD","SG9999001903.USD","LU1956131251.USD","LU0348735423.USD","LU1008478684.HKD","LU0348825331.USD","LU0417516571.SGD","02416","LU1226287529.USD","LU1861214812.USD","00909","BK1549","HXXD.SI","LU1211504680.USD","IE00B0169L03.USD","01651","LU1105468828.SGD","LU1439103000.SGD","LU1688375341.USD","02419","LU0348766576.USD","SG9999001440.SGD","BK1209","IE0009570106.USD","LU1993786604.SGD","GELYY","LU0128522157.USD","IE0003795394.USD","LU0328353924.USD","LU1655091459.SGD","LU0918141887.USD","LU1316542783.SGD","SG9999001226.SGD","LU2362540622.SGD","LU1226288170.HKD","00345","09896","BK1531","LU0235996351.USD","BK1539","BK1128","LU0700851271.USD","LU0143863198.USD","SG9999004311.SGD","SG9999014906.USD","LU1051769294.HKD","LU1303224171.USD","BK1189","81024","LU0329678170.USD","SG9999014674.SGD","LU0531970944.HKD","BK1126","HK0000252152.HKD","LU1718418525.SGD","BK1216","LU0823397103.USD","LU0084288322.USD","BK1599","LU0577902371.SGD","LU1282648689.USD","LU1515016050.SGD","LU2778985437.USD","BK1247","LU0043850808.USD","06100","LU0819121731.USD","LU1720050803.USD","BK1508","IE00B543WZ88.USD","IE0034224299.USD","LU0080751232.USD","LU0326950275.SGD","LU1880383440.USD","BK1160","BK1506","IE00B031J352.USD"],"gpt_icon":1},{"id":"1149194654","title":"ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.49 Million on December 22","url":"https://stock-news.laohu8.com/highlight/detail?id=1149194654","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149194654?lang=en_us&edition=fundamental","pubTime":"2025-12-22 17:56","pubTimestamp":1766397371,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that on December 22, 2025, the company repurchased 200,000 shares at a total cost of HK$2.49 million.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01477","BK1515","01672","BK1574","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":0.0807},{"period":"3month","weight":0.476},{"period":"6month","weight":0.2612},{"period":"1year","weight":2.4315},{"period":"ytd","weight":0.187}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0238},{"period":"6month","weight":0.0471},{"period":"1year","weight":0.3222},{"period":"ytd","weight":0.0372}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.143809},{"month":2,"riseRate":0.714286,"avgChangeRate":0.094063},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"ASCLETIS-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCLETIS-B,01672,ASCLETIS-B股票,ASCLETIS-B股票老虎,ASCLETIS-B股票老虎国际,ASCLETIS-B行情,ASCLETIS-B股票行情,ASCLETIS-B股价,ASCLETIS-B股市,ASCLETIS-B股票价格,ASCLETIS-B股票交易,ASCLETIS-B股票购买,ASCLETIS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}